What is Beaufort?
Beaufort CRO distinguishes itself by offering a unique clinical research organization experience, with a strategic emphasis on diagnostics and cutting-edge solutions designed to streamline regulatory and market authorization processes. Their comprehensive service portfolio encompasses clinical trial management, adept regulatory affairs support, robust quality assurance, and meticulous data management. Beaufort caters to a diverse clientele within the medical device and in vitro diagnostics sectors, leveraging a team that blends strategic foresight with deep operational expertise to guide clients toward successful product development and market entry. The organization serves both domestic and international markets, prioritizing accountability and collaborative partnerships to enhance the product-to-market journey.
How much funding has Beaufort raised?
Beaufort has raised a total of $927K across 2 funding rounds:
Debt
$350K
Debt
$577K
Debt (2020): $350K with participation from PPP
Debt (2021): $577K led by PPP
Key Investors in Beaufort
PPP
Public-Private Partnership
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Beaufort?
With the recent major strategic investment, Beaufort is poised to accelerate its growth and enhance its service offerings in the competitive CRO landscape. The substantial capital infusion is expected to fuel advancements in their diagnostic and regulatory solutions, potentially expanding their market reach and deepening their expertise in clinical trial management. This strategic financing suggests a focus on scaling operations, investing in technology, and potentially pursuing new market opportunities within the medical device and IVD sectors. Beaufort's commitment to streamlining regulatory pathways and fostering collaborative client relationships will likely remain central to its forward-looking strategy, aiming to solidify its position as a leader in providing innovative CRO services.
See full Beaufort company page
